MiNK Therapeutics (NASDAQ:INKT – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $35.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 234.13% from the company’s previous close.
INKT has been the subject of a number of other research reports. Weiss Ratings downgraded shares of MiNK Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 12th. Wall Street Zen upgraded shares of MiNK Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $35.00.
Check Out Our Latest Analysis on MiNK Therapeutics
MiNK Therapeutics Trading Down 2.3%
MiNK Therapeutics (NASDAQ:INKT – Get Free Report) last issued its earnings results on Friday, May 15th. The company reported ($0.57) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.20. Equities research analysts forecast that MiNK Therapeutics will post -3.27 earnings per share for the current year.
Hedge Funds Weigh In On MiNK Therapeutics
A hedge fund recently bought a new stake in MiNK Therapeutics stock. DRW Securities LLC acquired a new stake in MiNK Therapeutics, Inc. (NASDAQ:INKT – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,677 shares of the company’s stock, valued at approximately $286,000. DRW Securities LLC owned approximately 0.55% of MiNK Therapeutics at the end of the most recent reporting period. Institutional investors own 2.87% of the company’s stock.
About MiNK Therapeutics
MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.
MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.
Featured Stories
- Five stocks we like better than MiNK Therapeutics
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
- Consumer-Driven Stocks Boost Buybacks, Including Visa’s $20B Plan
- Iran Ceasefire Trade: 3 Energy Stocks to Own if Oil Falls to $80
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
